Since its identification in 1993 (16), the tyrosine kinase receptor gene, rearranged during transfection (RET), which is an oncogenic driver when aberrantly activated in several malignancies including non-small-cell lung cancer (NSCLC), PTC and MTC (reviewed elsewhere; 17, 18) has emerged as an attractive therapeutic target in patients with RET-driven thyroid carcinoma (19). This evidence concerns the gene RET and thyroid gland carcinoma.